Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Analysis of the prognostic significance of selected morphological and immunohistochemical markers in ependymomas, with literature review.

Zawrocki A, Iżycka-Świeszewska E, Papierz W, Liberski PP, Zakrzewski K, Biernat W.

Folia Neuropathol. 2011;49(2):94-102. Review.

2.
3.

Adult ependymal tumors: prognosis and the M. D. Anderson Cancer Center experience.

Armstrong TS, Vera-Bolanos E, Bekele BN, Aldape K, Gilbert MR.

Neuro Oncol. 2010 Aug;12(8):862-70. doi: 10.1093/neuonc/noq009. Epub 2010 Feb 5.

4.

Immunohistochemical markers for prognosis of ependymal neoplasms.

Korshunov A, Golanov A, Timirgaz V.

J Neurooncol. 2002 Jul;58(3):255-70.

PMID:
12187959
5.

Immunohistochemical expression of cyclin D1 is higher in supratentorial ependymomas and predicts relapses in gross total resection cases.

de Andrade FG, Marie SK, Uno M, Matushita H, Taricco MA, Teixeira MJ, Rosemberg S, Oba-Shinjo SM.

Neuropathology. 2015 Aug;35(4):312-23. doi: 10.1111/neup.12195. Epub 2015 May 6.

PMID:
25946121
6.

Ependymoma gene expression profiles associated with histological subtype, proliferation, and patient survival.

Lukashova-v Zangen I, Kneitz S, Monoranu CM, Rutkowski S, Hinkes B, Vince GH, Huang B, Roggendorf W.

Acta Neuropathol. 2007 Mar;113(3):325-37. Epub 2007 Jan 31.

PMID:
17265049
7.

Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases.

Korshunov A, Golanov A, Timirgaz V.

J Neurol Sci. 2000 Aug 1;177(1):72-82.

PMID:
10967185
8.

Telomere maintenance and dysfunction predict recurrence in paediatric ependymoma.

Tabori U, Wong V, Ma J, Shago M, Alon N, Rutka J, Bouffet E, Bartels U, Malkin D, Hawkins C.

Br J Cancer. 2008 Oct 7;99(7):1129-35. doi: 10.1038/sj.bjc.6604652. Epub 2008 Sep 16.

9.

Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas.

Kurt E, Zheng PP, Hop WC, van der Weiden M, Bol M, van den Bent MJ, Avezaat CJ, Kros JM.

Cancer. 2006 Jan 15;106(2):388-95.

10.

Nestin expression identifies ependymoma patients with poor outcome.

Milde T, Hielscher T, Witt H, Kool M, Mack SC, Deubzer HE, Oehme I, Lodrini M, Benner A, Taylor MD, von Deimling A, Kulozik AE, Pfister SM, Witt O, Korshunov A.

Brain Pathol. 2012 Nov;22(6):848-60. doi: 10.1111/j.1750-3639.2012.00600.x. Epub 2012 May 30.

PMID:
22568867
11.

Ki-67 immunolabeling index is an accurate predictor of outcome in patients with intracranial ependymoma.

Wolfsberger S, Fischer I, Höftberger R, Birner P, Slavc I, Dieckmann K, Czech T, Budka H, Hainfellner J.

Am J Surg Pathol. 2004 Jul;28(7):914-20.

PMID:
15223962
12.

Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma.

Ridley L, Rahman R, Brundler MA, Ellison D, Lowe J, Robson K, Prebble E, Luckett I, Gilbertson RJ, Parkes S, Rand V, Coyle B, Grundy RG; Children's Cancer and Leukaemia Group Biological Studies Committee.

Neuro Oncol. 2008 Oct;10(5):675-89. doi: 10.1215/15228517-2008-036. Epub 2008 Aug 13.

13.

[Intracranial ependymomas in adult patients. Diagnosis and histological prognostic factors].

Figarella-Branger D, Metellus P, Barrié M, Maues de Paula A, Fernandez C, Polivka M, Vital A, Labrousse F, Vignaud JM, Laquerrière A, Rousselet MC, Lacroix C, Saikali S, Chapon F, Gontier MF, Chrétien F, Babin P, Rigau V, Vandenbos F, Peoc'h M, Kujas M, Chinot O, Gouvernet J, Giorgi R, Guyotat J, Jouvet A.

Neurochirurgie. 2007 Jun;53(2-3 Pt 1):76-84. French.

PMID:
17445840
14.

Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system.

Raghunathan A, Wani K, Armstrong TS, Vera-Bolanos E, Fouladi M, Gilbertson R, Gajjar A, Goldman S, Lehman NL, Metellus P, Mikkelsen T, Necesito-Reyes MJ, Omuro A, Packer RJ, Partap S, Pollack IF, Prados MD, Robins HI, Soffietti R, Wu J, Miller CR, Gilbert MR, Aldape KD; Collaborative Ependymoma Research Network.

Brain Pathol. 2013 Sep;23(5):584-94. doi: 10.1111/bpa.12050. Epub 2013 Mar 28.

PMID:
23452038
15.

Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype.

Rushing EJ, Brown DF, Hladik CL, Risser RC, Mickey BE, White CL 3rd.

Mod Pathol. 1998 May;11(5):464-70.

PMID:
9619600
16.

Expression of claudins relates to tumour aggressivity, location and recurrence in ependymomas.

Nordfors K, Haapasalo J, Sallinen PK, Haapasalo H, Soini Y.

Histol Histopathol. 2013 Sep;28(9):1137-46. doi: 10.14670/HH-28.1137. Epub 2013 Feb 20.

PMID:
23423606
17.

Descriptive epidemiology of ependymal tumours in the United States.

Villano JL, Parker CK, Dolecek TA.

Br J Cancer. 2013 Jun 11;108(11):2367-71. doi: 10.1038/bjc.2013.221. Epub 2013 May 9.

18.

Nucleolin overexpression is associated with an unfavorable outcome for ependymoma: a multifactorial analysis of 176 patients.

Chen C, Chen L, Yao Y, Qin Z, Chen H.

J Neurooncol. 2016 Mar;127(1):43-52. doi: 10.1007/s11060-015-2007-7. Epub 2015 Nov 28.

PMID:
26615563
19.

Prognostic factors in intracranial ependymomas in children.

Figarella-Branger D, Civatte M, Bouvier-Labit C, Gouvernet J, Gambarelli D, Gentet JC, Lena G, Choux M, Pellissier JF.

J Neurosurg. 2000 Oct;93(4):605-13.

PMID:
11014538
20.

Pediatric intracranial ependymomas: prognostic relevance of histological, immunohistochemical, and flow cytometric factors.

Zamecnik J, Snuderl M, Eckschlager T, Chanova M, Hladikova M, Tichy M, Kodet R.

Mod Pathol. 2003 Oct;16(10):980-91.

Supplemental Content

Support Center